Spyre Therapeutics (SYRE) Long-Term Deferred Tax (2022)
Spyre Therapeutics posted quarterly Long-Term Deferred Tax of $566000.0 for Q4 2022.
Spyre Therapeutics (SYRE) has 1 years of Long-Term Deferred Tax data on file, last reported at $566000.0 in Q4 2022.
- For the quarter ending Q4 2022, Long-Term Deferred Tax changed N/A year-over-year to $566000.0; the trailing twelve-month figure through Dec 2022 stood at $566000.0 (changed N/A YoY), and the FY2022 full-year result was $566000.0, changed N/A from the prior year.
- Long-Term Deferred Tax for Q4 2022 stood at $566000.0.
- Across five years, Long-Term Deferred Tax topped out at $566000.0 in Q4 2022 and bottomed at $566000.0 in Q4 2022.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn |
| 10 | Spyre Therapeutics | 5.55 Bn | 5.55 Bn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2022 | 566,000.00 |